Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor.
See our latest analysis for Danaher.
Against the leadership news backdrop, Danaher's share price has risen over the past week and quarter, with a 7 day share price return of 6.5% and a 90 day share price return of 25.0%. However, the year to date share price return is down 10.0% and the 5 year total shareholder return is down 25.3%, which suggests recent momentum has picked up after a weaker longer term trend.
If this kind of leadership change has you thinking about what else might be setting up for a shift, it could be a useful moment to scan 43 healthcare AI stocks.
After Danaher’s recent rebound, the stock now sits about 9% below both the average analyst price target and one estimate of intrinsic value. The key question is whether that gap still represents a genuine discount once the valuation is unpacked.
Most Popular Narrative: 9.3% Undervalued
Danaher is trading at $207.44 compared with a widely followed narrative fair value of about $228.61, which frames the recent rebound as only part of the story.
The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.
Want to see the engine behind that fair value gap? Revenue expectations, margin uplift and a reset future earnings multiple all sit at the core. Curious which assumptions really move the needle for Danaher’s valuation?
Result: Fair Value of $228.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Danaher’s story still carries real execution risk, particularly if bioprocessing demand remains soft or if changes to China’s reimbursement and procurement policies continue to pressure diagnostics revenue and margins.
Find out about the key risks to this Danaher narrative.
Next Steps
Given the mix of optimism and concern around Danaher, it makes sense to look at the full picture and not just the headlines. To see the balance between potential upside and the issues investors are watching, check out the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Danaher?
If Danaher's story has you thinking bigger about your portfolio, do not stop here. Use fresh data driven stock ideas to keep your watchlist sharp and future focused.
- Target steadier potential returns by checking companies screened for resilience through the 85 resilient stocks with low risk scores.
- Hunt for potential mispriced opportunities by reviewing the screener containing 20 high quality undiscovered gems before others catch on.
- Strengthen your core holdings with companies filtered using the solid balance sheet and fundamentals stocks screener (50 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com